Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Hepatitis B Virus – Epidemiology – Epidemiology Dashboard

Login to access report north_east
Contact sales account_box

Clarivate Epidemiology’s coverage of hepatitis B virus (HBV) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the total and diagnosed prevalence of HBV for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature markets and Europe and 10 years for the other countries we cover.

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology’s HBV forecast answers the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of HBV?
  • In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of HBV?
  • How will improvements in survival change the number of people living with a diagnosis of HBV?
  • Of all people diagnosed with HBV, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HBV over the forecast period?

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following HBV subpopulations:

  • Total hepatitis B prevalent cases
  • Total prevalent cases by diagnosis status
  • Diagnosed prevalent cases by HBeAg status
  • Diagnosed prevalent cases by liver status
  • Diagnosed prevalent cases by treatment status

Note: Coverage may vary by country.

Table of contents

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus, described as deep vein thrombosis (DVT) or pulmonary embolism (PE), depending on the vein affected. Anticoagulants…
north_east
Report
Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult ADHD (US)
Attention-deficit / hyperactivity disorder (ADHD), a common childhood neurodevelopmental condition that can persist into adulthood, affects about 6% of U.S. adults, or approximately 15.5 million…
north_east
Report
Cystic Fibrosis – Unmet Need – Unmet Need – Cystic Fibrosis (US EU)
Cystic fibrosis (CF) is a genetic disease associated with more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. These mutations cause aberrant…
north_east
Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Asthma (US)
Two types of pharmacotherapies are used in parallel to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via…
north_east
Report
Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)
Hyperkalemia is defined as a serum potassium level above 5.0 mEq/L. This report covers the management of chronic hyperkalemia through diuretic therapy, correcting metabolic acidosis when present,…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east